Technology
Health
Pharmaceutical

Reata Pharmaceuticals

$90.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.07 (3.52%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell RETA and other stocks, options, ETFs, and crypto commission-free!

About RETA

Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Employees
123
Headquarters
Irving, Texas
Founded
2002
Market Cap
2.62B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
182.57K
High Today
$90.38
Low Today
$86.68
Open Price
$87.54
Volume
173.01K
52 Week High
$104.53
52 Week Low
$47.50

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2016 IPO
US
North America

RETA Earnings

-$1.08
-$0.67
-$0.26
$0.15
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.